Join Growin Stock Community!

Cogent biosciences, inc.COGT.US Overview

US StockHealthcare
(No presentation for COGT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

COGT AI Insights

COGT Overall Performance

COGT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

COGT Recent Performance

-2.96%

Cogent biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

COGT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

COGT Key Information

COGT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

COGT Profile

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Price of COGT

COGT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

COGT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.03
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1320.63
PB Ratio
11.53
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.03
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1320.63
PB Ratio
11.53
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is COGT's latest earnings report released?

    The most recent financial report for Cogent biosciences, inc. (COGT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating COGT's short-term business performance and financial health. For the latest updates on COGT's earnings releases, visit this page regularly.

  • How much debt does COGT have?

    As of the end of the reporting period, Cogent biosciences, inc. (COGT) had total debt of 238.8M, with a debt ratio of 0.25. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does COGT have?

    At the end of the period, Cogent biosciences, inc. (COGT) held Total Cash and Cash Equivalents of 312.43M, accounting for 0.33 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is COGT's EPS continuing to grow?

    According to the past four quarterly reports, Cogent biosciences, inc. (COGT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.61. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of COGT?

    Cogent biosciences, inc. (COGT)'s Free Cash Flow (FCF) for the period is -79.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 31.76% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.